Istituto Superiore di Sanità
Italian National Institute of Health

ISTITUTO SUPERIORE di SANITA’ (ISS)

is the leading technical and scientific public body of the Italian National Health Service. Its activities include research, clinical trials, control, training and advise in the interest of public health protection.

The Institute is organized in 7 Departments and 8 National Centres carrying out scientific research in a wide variety of fields.

Research priorities are based on those set forth in the National Health Plan.

Cooperation activities include participation, promotion and implementation of projects financed both by multilateral organisations.
ISS is unique

symbiosis between research activity and service activity

to meet the demand for health and respond to issues raised by the State, the EU, the regions, the local health authorities and hospitals

European (EU-RL) and National (NRL) Reference Laboratories

Reg. (CE) 882/2004

- EU-RL for Escherichia coli
- EU-RL for Chemical elements in food of animal origin
- EU-RL for Parasites
- NRL for Escherichia coli
- NLR for Trichinella
- NRL for Quality and security of milk
- NRL for Viral contamination of mollusc
- NRL for Micotoxins
- NRL for Heavy metals
- NRL for Drug residuals in food of animal origin
- NRL for Hidrocarbon polycyclic aromatic
- NRL for Pesticides in food
- NLR for Material in contact with food
Department of DRUG RESEARCH & EVALUATION

The mission: to contribute to public health by controlling the quality, efficacy and safety of drugs and through research into new drugs and treatments for human diseases.

Department of VETERINARY PUBLIC HEALTH AND FOOD SAFETY

The mission: to contribute to protect human health through the development of knowledge, tools and strategies aimed at ensuring food safety, zoonosis control and proper life and nutrition styles.
DEPARTMENT OF INFECTIOUS, PARASITIC and IMMUNE-MEDIATED DISEASES

Head of Department: Prof. Giovanni Rezza

**Mission:** to FIGHT DISEASES due to viruses, bacteria, fungi and parasites as well as to STUDY DISEASES due to disregulation of the immune system. Special emphasis is devoted to poverty-related diseases (AIDS, TB, malaria) and Neglected diseases.

The Department is organized into 12 Laboratories

UNIT OF GASTROENTERIC AND TISSUE PARASITIC DISEASES

- 18 persons are working at the Unit

- The main topics covered by the Unit are:
  - parasitological, serological and molecular diagnoses of foodborne parasites and parasitic diseases;
  - epidemiological investigations;
  - molecular taxonomy;
  - molecular epidemiology;
  - basic research on biochemistry and cellular biology;
  - production of reference material;
  - PT organization;
  - organization of workshops and training courses.
UNIT OF GASTROENTERIC AND TISSUE PARASITIC DISEASES

• The Unit has been appointed as:
  – International Trichinella Reference Center since 1988
  – OIE reference Laboratory for Trichinellosis since 1992
  – National Reference Laboratory for Trichinella, since 2006
  – European Union Reference Laboratory for Parasites, since 2006

• The target parasites and related diseases are:
  – Protozoa: Cryptosporidium, Dientamoeba, Giardia, Toxoplasma
  – Helminths: Opisthorchis, Fasciola, Diphyllobothrium, Taenia, Echinococcus, Trichinella
  – Human intestinal parasites
WP1–2
PEZZOTTI PATRIZIO – Survey statistical evaluation
FENICIA VESCIO – Survey statistical evaluation
GALATI FABIO – EE Registry and databases
DI BENEDETTO CORRADO – EE Registry and databases
ROSSI PATRIZIA – EE Registry

WP3
PONZI MARTA – Proteomic and Transcriptomic
ALESSIA POSSENTI – Proteomic and Transcriptomic

WP4
GOMEZ MORALES MARIA……. – Drug formulations
GALLINELLA BRUNO – HPLC
ROBERTO CIRILLI – HPLC and enantiomers
MARANGHI FRANCESCA – Toxicology
TASSINARI ROBERTA – Toxicology
Partner 2 – WP1
University of Pavia
WHO Collaborative Centre
for the Clinical Management of Cystic Echinococcosis

US screening of CEE population
and CE registries

ENRICO BRUNETTI - Responsible for the activity of Partner 2
MD, Assistant Professor in Infectious diseases, Director WHO CC
Weekly clinic for CE in the Ultrasound Unit of Infectious Diseases

CARLO FILICE
MD, Associate Professor in Infectious diseases
Director of the Ultrasound Unit of the Department of Infectious Diseases

FRANCESCA TAMAROZZI - Coordinating the activity of Partner 2
DVM MD PhD; Resident in Microbiology and Virology
Weekly clinic for CE in the Ultrasound Unit + Italian Registry of CE

MARA MARICONTI BSc, PhD, Post-doctoral researcher
Diagnosis and Biology of Cystic Echinococcosis + Italian Registry of CE

FRANCESCA RINALDI MD, Scholarship
Surgery for CE + Italian Registry of CE

JACOPO NICOLETTI MD, Scholarship
Costs of CE treatment + Italian Registry of CE

VALERIA MERONI PhD, Assistant Professor in Infectious diseases; Laboratory for Toxoplasmosis
Serum Bank CE
NEW PATIENTS WITH SUSPECTED CE REFERRED TO OUR CENTRE

NEW CE CASES PER YEAR

NEW CE CASES PER YEAR FROM EASTERN EUROPE
CLINICAL MANAGEMENT

Watch and Wait 32%

Treatment 68%

CE ITALIAN REGISTRY

Registro Italiano dell’Echinococcosi Cistica

Chi siamo


Coordinatore: Enrico Bassetti, Primo consigliere, Comitato di Collaborazione dell’Organizzazione Mondiale della Sanità per la Gestione Tecnica della Echinococcosi Cistica, Università di Padova e Dipartimento di Parassiti infettivi e malattie infettive di Padova. Tel. 0498 301159.

Responsabile del database: KBC e dell’applicativa web Codice (0490/049), Istituto Superiore di Sanità, ISTAT, CENTI, Informatica, Roma; tel. 06 4990242.
Immunoblotting with Human Native Antigen Shows Stage-Related Sensitivity in the Serodiagnosis of Hepatic Cystic Echinococcosis

Mara Marconi, Chiara Bazzocchi, Francesca Tamaruzi, Valeria Meroni, Francesca Genco, Roberta Maserati, and Enrico Brunetti

![Immunoblotting result images]
The Spanish National Research Council (CSIC) is the largest public institution dedicated to research in Spain and the third largest in Europe. It belongs to the Spanish Ministry of Economy and Competitiveness.
The overall objective of this group is to develop new strategies for the prevention and control of animal parasites and parasitic zoonoses, based on a thorough knowledge of the parasites and their relationships with the host.

Our research aims at the identification and characterization of parasite molecules that interact with the host, and the definition of their usefulness in diagnosis and vaccination.

Our final goal is reaching applicable tools, in collaboration with private biotech companies.

We mainly work in echinococcosis, schistosomiasis and ticks. Also in fasciolosis, cysticercosis, amebiasis and giardiasis.
FACILITIES

Two labs ~ 100 s.m

Molecular Biology Central Service
http://www.imasa.csic.es/biologia-molecular1

Freezer room
COLENTINA CLINICAL HOSPITAL
Bucharest, Romania

Carmen-Michaela CRETU
Parasitology Department
Colentina Clinical Hospital
University of Medicine and Pharmacy “C. Davila”
Bucharest, Romania

- Build in 1856
  - 800 beds
  - 24 Departments

- Parasitology Department
  - 25 beds
  - Outpatients unit
  - 5 clinicians
  (3 involved in the study)
RESEARCH CENTER
(CDPC)

EU Funds - Operational program
“Increasing Economical Competitivity”

POS CEE: Project 112/2598
Code SMIS-CSNR
17 million Euro

TEAM WORK
Scientists

PARASITOLOGY

Assoc Prof Carmen-Michaela CRETU
MD, PhD, DTM&H
CTH*

Ass Prof Loredana Gabriela POPA
MD, PhD

Dr Corina Manuela CONSTANTIN
MD, PhD

Ass Prof Cerasela Cristiana DRAGOMIRESCU
MD, PhD student

EPIDEMIOLOGY / PH

Dr Denisa Georgiana JANTA
MD, EPIET-Alumni

Prof Ioan Mircea POPA
MD, PhD, MPH

Prof Mircea BEURAN
MD, PhD

Ass Prof Bogdan MASTALIER
MD, PhD

Ass Prof Alexandru Cosmin POPA
MD, PhD

Dr Adrian ZARAFIN
MD, PhD

1 Technician
2 Nurses
Administrative staff

- Manager: Dr. Bogdan ANDREESCU
- Financial officer: Maria DINESCU
- Administrative:
  - Mirela ALEXE
  - Angelica LUNGANA
  - Mariana ENACHE
  - Carmen GHEORGHE

PARASITOLOGY DEPARTMENT
CDPC

- Research laboratories:
  ✓ Serology - Automat ELISA
  ✓ Molecular Biology – classic PCR
  ✓ Coprology
- **US examination**: Aloca Prosound 7
- **4 beds** – facilities to implement PAIR technique

**Connection with:**
- Surgery Departments in Colentina Hospital and Clinical Emergency Hospital Floreasca, Bucharest
- University of Medicine and Pharmacy, Bucharest
- National Institute of Public Health – National Center for Surveillance and Control of Transmitted Diseases
<table>
<thead>
<tr>
<th>Partner No</th>
<th>Short name</th>
<th>Country</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 3          | UNIPV CCH  | Italy-Romania | **US screening in Romania 2004, 2006**  
Study on the epidemiology of *Echinococcus* spp. in hyperendemic areas from Ialomita and Buzau counties - Romania - organized by the Romanian Society of Parasitology, in collaboration with WHO Informal Working Group of Cystic Echinococcosis members (Italy, Germany, USA) |
| 4          | CCH SHATIP D | Romania-Bulgaria | **Systematic Review of effectiveness of Benimidazoles in CE** (Stojkovic et al., PLoS NTD 2009)  
**EchinoMEDREV** - Systematic review on Cystic Echinococcosis - Organized by University of Heidelberg, 2005-2006 (participating 11 states from Europe) |
| 5          | UNIPV CCH HUSM | Romania-Turkey | Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans  
(Brunetti et al., Acta Tropica, 2010)                                                                                                                                                   |

**Partners involved in Consortium**

<table>
<thead>
<tr>
<th>Partner No</th>
<th>Short name</th>
<th>Country</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 1          | ISS CCH    | Italy-Romania | **TRICHIPORSE**  
FP 5 Project, 2001-2004  
Safe pork and horse meat on EU markets: early and unbiased diagnostic tests for *Trichinella* - TRICHIPORSE Contract QLRT-2000-01156 (Carmen Cretu -Coordinator for Romanian Partner) |
| 2          | CCH UNIPV  | Romania-Italy | **Short Course on Abdominal US in Infectious Diseases and Tropical Medicine** 2007-2009                                                                                                                    |
| 3          | CCH UNIPV  | Romania-Italy | **Molecular characterization of Echinococcus granulosus in south-eastern Romania: evidence of G1-G3 and G6-G10 complexes in humans** (CMI. Picoli et al, 2012)                                           |
| 4          | CSIC UNIPV CCH | Spain-Italy-Romania | **Identification of gaps and research priorities in CE for the FP/financed platform “Disease Control Tools”** (http://www.discontools.eu)  |
National Research Projects on Echinococcosis

- **Study on efficacy of albendazole treatment in human hydatidosis** - 1994-1995 – Project under auspices of Romanian Academy of Medical Sciences (Carmen-Michaela Cretu - investigator)

- **Study of parasiticidic effect of different substances used intra-operative to inactivate hydatid cysts.** 2007-2008; **Contract 123/21.04.2008** Romanian Academy of Medical Sciences (University if Medicine and Pharmacy “C. Davila”, Bucharest - Carmen-Michaela Cretu - investigator)

- **Studies on molecular epidemiology in echinococcosis/hydatidosis in humans and animals in South and North-West of Romania** (ECHINOROM) 2008-2012: PN2 Contract: 52161/2008 - University of Medicine and Pharmacy “C. Davila” Bucharest:(Carmen-Michaela Cretu - principal investigator)

- **Immunological, molecular-biological and sero-epidemiological investigations on echinococcosis and toxocariasis – parasite-zoonoses of great medical – social importance.** **Contract DTK 0279/23.12.2009** (2009-2012) - National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria - University of Medicine and Pharmacy, Bucharest, Romania (Carmen-Michaela Cretu - Principal investigator Romanian Partner)
THANK YOU!
Hacettepe Radiology

Okan Akhan, MD
Prof. of Radiology
Hacettepe Uni
School of Medicine
Ankara

- Founded in 1958
- Permanant staff
  - 15 Full Prof.
  - 9 Asc. Prof.
  - 2 Assistant Prof.
  - 2 Instructors
- Residents
  - 30
Hacettepe Radiology

- MRI 4
- CT 6
- US 15
- Mammography 3
- Conventional X-Ray 12
- Suits for Interventions 5
  - 2 for Non-Vascular
  - 3 for Vascular

Hacettepe Radiology

- Neuro radiology
- Thoracic radiology
- Abdominal radiology
- Musculoskeletal radiology
- Pediatric radiology
- Cardiovascular radiology
- Breast imaging
- Interventional radiology
Hacettepe Radiology

- Number of the patients: 436,000 / year
  - US: 37,000
    - Doppler: 7,000
  - CT: 54,000
  - MRI: 31,000
  - Mammography: 9,250
  - Conventional Radiology: 264,000
  - Non-vascular Intervention: 10,000
  - Vascular Intervention: 4,400

Hacettepe Radiology

- Number of the patients
  - Non-vascular Intervention: 10,000/year
    - 3 academicians
  - Vascular Intervention: 4,000/year
    - 6 academicians
<table>
<thead>
<tr>
<th>Name</th>
<th>Papers</th>
<th>Citations</th>
<th>h-index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof. Dr. Ferhun Balkancı</td>
<td>120</td>
<td>1358</td>
<td>17</td>
</tr>
<tr>
<td>Prof. Dr. Mustafa Arıyürek</td>
<td>59</td>
<td>602</td>
<td>14</td>
</tr>
<tr>
<td>Prof. Dr. Okan Akhan</td>
<td>199</td>
<td>2578</td>
<td>29</td>
</tr>
<tr>
<td>Prof. Dr. Muhtar Özmen</td>
<td>82</td>
<td>1163</td>
<td>18</td>
</tr>
<tr>
<td>Prof. Dr. İlyas Topçu</td>
<td>136</td>
<td>2043</td>
<td>23</td>
</tr>
<tr>
<td>Prof. Dr. Figen Demirkazık</td>
<td>46</td>
<td>451</td>
<td>13</td>
</tr>
<tr>
<td>Prof. Dr. Deniz Akata</td>
<td>97</td>
<td>685</td>
<td>13</td>
</tr>
<tr>
<td>Prof. Dr. Murat Haliloglu</td>
<td>77</td>
<td>586</td>
<td>12</td>
</tr>
<tr>
<td>Prof. Dr. Saruhan Çekirge</td>
<td>126</td>
<td>1581</td>
<td>18</td>
</tr>
<tr>
<td>Prof. Dr. Üstün Aydıngöz</td>
<td>54</td>
<td>440</td>
<td>13</td>
</tr>
<tr>
<td>Prof. Dr. Meltem Gülün</td>
<td>25</td>
<td>285</td>
<td>10</td>
</tr>
<tr>
<td>Prof. Dr. Kader Kari Oğuz</td>
<td>83</td>
<td>668</td>
<td>13</td>
</tr>
<tr>
<td>Prof. Dr. Muşafu Karçaaltıncaba</td>
<td>125</td>
<td>744</td>
<td>14</td>
</tr>
<tr>
<td>Prof. Dr. Barbaros Çil</td>
<td>118</td>
<td>781</td>
<td>13</td>
</tr>
<tr>
<td>Prof. Dr. Deniz Akınç</td>
<td>51</td>
<td>352</td>
<td>11</td>
</tr>
<tr>
<td>Prof. Dr. Anıl Arat</td>
<td>29</td>
<td>564</td>
<td>11</td>
</tr>
<tr>
<td>Prof. Dr. Tuncay Hazmoğlan</td>
<td>85</td>
<td>354</td>
<td>10</td>
</tr>
<tr>
<td>Doç. Dr. BilgeEigen</td>
<td>30</td>
<td>112</td>
<td>6</td>
</tr>
<tr>
<td>Doç. Dr. Erhan Akpınar</td>
<td>67</td>
<td>235</td>
<td>9</td>
</tr>
<tr>
<td>Doç. Dr. Bora Peyirciçölü</td>
<td>60</td>
<td>296</td>
<td>10</td>
</tr>
<tr>
<td>Doç. Dr. Serdar Geyik</td>
<td>36</td>
<td>335</td>
<td>11</td>
</tr>
<tr>
<td>Doç. Dr. Kivikom Yavuz</td>
<td>37</td>
<td>321</td>
<td>11</td>
</tr>
<tr>
<td>Doç. Dr. Berna Oğuz</td>
<td>21</td>
<td>125</td>
<td>6</td>
</tr>
<tr>
<td>Mean</td>
<td>76.6</td>
<td>725</td>
<td>13.2</td>
</tr>
<tr>
<td>Total</td>
<td>1763</td>
<td>16670</td>
<td></td>
</tr>
</tbody>
</table>

**Hacettepe Radiology**

- Papers published in International Journals
  - 70 / year
Hacettepe Radiology

- Papers published on *Echinococcus granulosus* in International Journals
  
  20

- Studies which are going to be published
  
  10

Study group

- Prof. Dr. Okan Akhan
- Prof. Dr. Devrim Akıncı
- Ass. Prof. Türkmen Çiftçi
- Dr. Burcu Akpınar
Prof. Devrim Akıncı
Dr. Türkmen Çiftçi

Dr. Burcu Akpınar
One coordinator

- Organise the daily work in the survey region
HERACLES
BULGARIA
SHATIPD

KICK OFF MEETING
17-18 December 2013, Roma – Italy

Research Group
Sofia
Specialised Hospital for Infectious and Parasitic Diseases “Prof. J. Kirov” (SHATIPD)

University Hospital “Queen Joanna” (ISUL)

Multi-profile Hospital for Active Medical Treatment and Emergency Medicine "N. Pirogov”

Local specialists in endemic regions
Specialised Hospital of Infectious and Parasitic Diseases “Prof. J. Kirov” Sofia

Bild in 1939 r. 120 beds

Medical doctors:
• Specialists of Infectious diseases - 28
• Specialists of Parasitic diseases – 5
• Pediatrists - 10
• Rentgenology doctor – 1
  Making US to patients – 4 of physicians

Medical laboratory assistants and Nurses

Administration
Consultants

---

Structural units

Consultation office
Laboratory:
• clinical,
• parasitological
• microbiological
US room
Rentgen
Three Clinics:
Clinic neuroinfections and transmissible infections

Clinic with two sectors:
- For the treatment of viral hepatitis, intestinal, parasitia and tropical diseases
Acquired Immune Deficiency

Clinic Children's Infectious Diseases - 2 sectors:
- For children til 2 years
- Above 2 years

Department of Infectious Diseases, Parasitology and Tropical Medicine, Medical University – Sofia

Intensive sector
Department of Infectious Diseases, Parasitology and Tropical Medicine, Medical University – Sofia

Bulgarian Society of parazitologia

Medical University – Sofia
PAIR RESEARCH GROUP
University Hospital “Queen Joanna-ISUL” Sofia, Clinic of Gastroenterology
Prof. Nikola Grigorov, MD, PhD, DMSc - first start using and still performing PAIR in Bulgaria
Branimir Golemanov, MD, PhD - PhD on PAIR

SURGERY RESEARCH GROUP
University Hospital “Queen Joanna” Sofia
Prof. Damian Damianov, MD, PhD, DMSc, President of the Union of Scientists in Bulgaria, President of Bulgarian Surgical Society

Hospital for Active Medical Treatment and Emergency Medicine “Pirogov” – Sofia
Prof. Aleksandar Tcherveniakov, MD, PhD. Head of the department of surgery

Prof. Rosen Drebov, Head of the department of pediatric surgery
Chief Health Inspector in the Ministry of Health
Dr. Angel Kunchev
Pendik Veterinary Control Institute (PVCI), Turkey
Participant No: 7
Acronym: PVCI

Gülay VURAL
PVC1 serves to 12 provinces in Thrace and Marmara Region in some parts of the duties. It also serves to all country with the other duties such as biological production, diagnostics and drug quality controls.

The institute runs many research activities, produce vaccines and biological materials organize workshops and seminars for field vets and also have diagnostic services for the general public. The research group publishes a scientific journal.
The institute has established bounds with organizations such as FAO, OIE, EU, VLA, IAEA, AFFSA, WHO-MZCC and developed common projects and strategies.

Pendik Institute is now produced 17 vaccines and 22 serums, antigens and biological materials. Right now, the Institute continues to serve with 23 laboratories under 3 departments. (www.penvet.gov.tr).

The Institute has Experimental Animal Unit that supports medical researchers for experiments by mice, guinea pigs, rabbits and rats section.

Drug Quality Control Laboratory, under Pharmacology Department, is a reference laboratory assigned for the quality control of the veterinary pharmaceuticals including Benzimidazole group drugs by means of HPLC, LC-MS/MS.
Role and main tasks:
PVCI participates in WP4 in total. Main tasks of WP4 is to determine in an invivo model, the protoscolicidal effects of ABZ against E. granulosus and whether HP-βCD improves the oral bioavailability of BZs, consequently the anthelmintic effectiveness. WP4 also support WP2 by collecting 500 animal samples (blood and parasite cysts) and 500 additional blood samples from negative animals.

Previous experience at PVCI
PVCI has many national and international activities and research projects, IAEA projects about theileriosis and PPR; Capacity Building For The Control of Avian Influenza Through Tecnology Transfer And Training. (EU F6 Project, SSPE-CT-2006-44462; OIE Brucellosis Laboratory Twinning Project. Animal Health & Veterinary Laboratories Agency (parent laboratory), Pendik Veterinary Control Institute (candidate laboratory).
PVCI also has several surveillance programmes for various infectious and parasitic diseases (eg. AI, PPR, brucellosis, echinococcosis etc.)
**PVCI Department of Parasitology** has some activities about the Project issue. 
The department defined some genotypes (strains) of *E. granulosus* getting TUBITAK (Turkish Scientific Technological Research Council) sources; 
Organized test trial for Intestinal Scraping Technique between European Union Reference Laboratory for Parasites (Department of Infectious, Parasitic and Immunomeditated Diseases Istituto Superiore di Sanità) in Italy 
PVCI had a research activity with University of Melbourne on production of *E. granulosus* recombinant DNA vaccine (EG95) for sheep and goats. 
The department also has ISO/IEC 17025 certificate.

---

**Short profile of key staff members involved in the project**  
**Gulay VURAL, DVM, PhD** is a parasitologist.  
**Topic:** Echinococcosis. She had Post doctoral research on “Variability of the host protective EG95 vaccine antigen in G6 and G7 genotype variants” with a group of people from University of Melbourne, School of Veterinary Science, Molecular Parasitology, Australia 2003-2004 period. After that, she has several researches on “Investigation of the potential to create a combined hydatid/enterotoxemia vaccine for livestock”. She has been working as head of Parasitic Vaccines Production Department of the Institute. Dr. Vural (leader of WP4) will be planned all activities in WP4, collection of samples, infection of experimental animals, administration drugs agains to hydatidosis, deliver of whole samples to WP2 and Drug Laboratory, deliver of results and reports.
Ozlem BAGCI, DVM, PhD is a Physiologist/Parasitologist
Topic: Echinococcosis, Theileriosis. She has worked on
parasitic vaccines (Attenuated Theileria annulata vac) since from 1998. She involved in the project
“Determination of Echinococcus granulosus genotype
group in Turkey by cytochrom c oxidase subunit 1 gene”
actively. Dr. Bagci will be handled experimental animals by
making seconder hydatidosis.

E. Ozan CAKIR, DVM, PhD is a Pharmacologist/ Toxicologist
Topic: Drug Quality Control, Pharmacokinetic, Instrumental
analysis and Heavy metal intoxication. He has worked on
pharmacology department since from 2006. He has been
working as head of Drug Quality Control Department of the
Institute. Dr. Cakir will be worked on making dose of drugs
against hydatidosis and HPLC analysis in WP4.
Serafettin OZTURK, is a Technician. He has been work for Department of Parasitology since 1997. Mr. Ozturk is responsible maintenance of experimental animal and their health.

Additional staff:
Mevlut DEMIRBAS Chemist
Sezai ARSLAN DVM, PhD
Hulya OZENLI DVM
International Fund Raising

ALTA

Founded in 1998
ALTA is service-provider company specialized in developing and managing projects financed by the European Commission.

ALTA people will support you from the idea to the realization of the project proposal helping in finding the proper strategy, forming the European Consortium, putting your science in the most appropriate administrative and management framework.

Once granted, ALTA will be your partner in running the project in any part but ... science.
What we do

We provide assistance to obtain and manage grants acting at the level of:

- Preparation of the project proposal
- Proposal Submission
- Preparation of consortium agreement
- Contract Negotiation
- Assisting in co–ordination (managing, monitoring and co-ordinating the project)
- Reporting on science and costs
- Dissemination
- Training

The Added Value

Scientists translating management

- ALTA is the only company for construction and management of research and development projects completely devoted to Life Sciences

- ALTA team is a perfect blend between project managers with great knowledge of public funding rules and scientists with expertise in immunology, microbiology, pharmacology and chemistry.

We believe that a successful project can only be constructed with a facilitator role of managers with a strong scientific background
Strength points

- Focus on life sciences projects
- Global networking of excellent scientists
- Robust track records of successful projects
- Great knowledge of EU R&D programs such as Cooperation, IMI and Ideas
- Long experience in training programs and in complementary skill teaching
- Leading position in science dissemination
- International operations covering the whole world
**7th FRAMEWORK PROGRAM EUROPEAN GRANTS**

Success rate (over the threshold): 62%

Financed projects: 27%

---

**EU contribution:** €2,999,500

- **Participants:** 11
- **Duration:** 3 years

**EU contribution:** €1,100,000

- **Participants:** 7
- **Duration:** 2 years

**EU contribution:** €5,524,704

- **Participants:** 13
- **Duration:** 3 years

**EU contribution:** €10,836,201

- **Participants:** 11
- **Duration:** 5 years

**EU contribution:** €4,196,460

- **Participants:** 10
- **Duration:** 3 years

**EU contribution:** €2,999,860

- **Participants:** 11
- **Duration:** 4 years

**EU contribution:** €2,965,207

- **Participants:** 12
- **Duration:** 5 years

**EU contribution:** €2,999,300

- **Participants:** 10
- **Duration:** 4 years

**EU contribution:** €29,000,000

- **Participants:** 42
- **Duration:** 5 years

**EU contribution:** €5,909,690

- **Participants:** 10
- **Duration:** 5 years

**EU contribution:** €5,989,000

- **Participants:** 16
- **Duration:** 5 years

**EU contribution:** €18,200,000

**EFFIA in kind contribution:** €9,600,000

- **Participants:** 9 EFPIA MEMBER COMPANIES, 24 ACADEMIC INSTITUTES, 2 SMEs
- **Duration:** 5 years

**EU contribution:** €5,987,800

- **Participants:** 11
- **Duration:** 5 years

**EU contribution:** €5,892,178

- **Participants:** 11
- **Duration:** 5 years

**EU contribution:** €5,982,400

- **Participants:** 11
- **Duration:** 5 years

**EU contribution:** €2,861,500

- **Participants:** 9
- **Duration:** 4 years

---

**New FP7 Projects**

**Atheroflux**

- **EU contribution:** €5,987,800
- **Participants:** 11
- **Duration:** 5 years

**AtheroCell**

- **EU contribution:** €5,892,178
- **Participants:** 11
- **Duration:** 5 years

**BIOCOG**

- **EU contribution:** €5,982,400
- **Participants:** 11
- **Duration:** 5 years

**HERACLES**

- **EU contribution:** €2,861,500
- **Participants:**
- **Duration:** 4 years
ALTA and TRAINING PROJECTS
Complementary Skills Courses

Within EIMID EST, ALTA organised three Complementary Skills Courses, designed to provide knowledge on aspects not directly related to Scientific Research, such as Intellectual Property, Ethical Issues, Fund Raising, etc.

**Legal Complementary Skills for Life Scientists**
was designed in order to enable participants with a scientific background in life sciences to understand more properly the legal issues related to their field.

**Knowledge for Bio-entrepreneurship**
was designed in order to enable the participants to acquire a better understanding of legal and economic aspects governing the financing and the commercial development of their innovative scientific projects.

**Scientific Communication to General Public**
was designed in order to enable the participants to acquire a better understanding of the different available communication media and of their different languages.

---

Workshop organized in collaboration with Brazilian partners

**Modelling Acute And Chronic Inflammatory Diseases In Animals**
September 17th-19th, 2013 – Rio De Janeiro, Brazil

**Intellectual Property and Technology Transfer issues in Health Science and their impact on product development at the global level**
October 18th-20th, 2012 - Florence, Italy
Communication

Within the MUVAPRED (Mucosal Vaccines for Poverty Related Diseases), project funded by the European Commission, ALTA organized the photo exhibition “Hands for Life, hands for Hope” to sensitize general public toward the poverty related diseases, scientific research and vaccines.

The photo assays have been exhibited in several locations:
- Eu Commission - Exhibition Berlaymont - Brussels - Belgium - December, 2005
- Novartis Vaccines Research Center - Siena - Italy - August, 2006
- Made in Tomorrow Triennale - Milan - Italy - May, 2007
- National Institutes of Health - Clinical Center - Bethesda - U.S.A. - December, 2007
- St. George’s Hospital - London - U.K. - September, 2008
- City Hall – London - U.K. - December, 2008
- Santa Maria della Scala - Siena - Italy - November, 2009
- Castel Grande - Bellinzona - Switzerland - July, 2010
- Novartis Vaccines Institute for Global Health - Siena - Italy - December, 2010

Dissemination activities

LEAFLET and BROCHURES

WEBSITES

NEWSLETTERS
THANK YOU FOR YOUR ATTENTION
AND
VISIT OUR WEB SITE
www.altaweb.eu
About us

Vircell is a biotechnology company established from **private capital in 1991**.

Founded by **clinical microbiologists** with previous experience working in hospitals, our activity is focused on the production of ready-to-use kits for the **diagnosis of esoteric infectious diseases** by means of different techniques.

Our international projection translates into **worldwide** export of our products. Vircell is well introduced in laboratories of more than 60 countries in Europe, Latin-America, Asia and Middle East.
Mission: VIRCELL is a microbiology-biotechnology company which develops, manufactures, markets, sales and distributes ready-to-use kits for the diagnosis of esoteric infectious diseases. Our business culture is based upon our people, our high quality products, science, our know how and support through R&D.

Since its foundation VIRCELL has three main objectives:

1. To produce reagents of the highest quality
2. To maintain along the whole process a clear customer orientation that can be seen all the way from the product concept to the after-sales service.
3. To develop innovative products for obtaining significant advances.

Vision: We pursue to become a gold standard for the microbiology and biotechnology sector by developing innovate products and techniques for the diagnosis of esoteric infectious diseases.

In a two years time frame, we aim for a qualitative and quantitative major turn around to become an international company by consolidating our global presence.

The team

<table>
<thead>
<tr>
<th>Lab technicians</th>
<th>Bachelor Science</th>
<th>PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>35%</td>
<td>44%</td>
<td>21%</td>
</tr>
</tbody>
</table>

Mission & Vision

The team

- GENERAL MANAGEMENT
  - Dr. Joaquín Mendoza
- TECHNICAL MANAGEMENT
  - Dr. Antonio de la Peña
- REGULATORY AFFAIRS MANAGEMENT
  - Dr. Antonio de la Peña
- PROJECT DIRECTOR
  - M. José Antonio
- TRAINING
  - M. José Antonio
- QUALITY ASSURANCE
  - M. José Antonio
- QUALITY CONTROL
  - M. José Antonio

PRODUCTION

- CELL CULTURE
  - M. José Antonio
- SALES & MARKETING
  - M. José Antonio
- OPERATIONS
  - M. José Antonio
- RAQ
  - M. José Antonio

SALES & MARKETING

- MARKETING
  - M. José Antonio
- SALES
  - M. José Antonio
- CUSTOMER SERVICE
  - M. José Antonio

OPERATIONS

- HUMAN RESOURCES
  - M. José Antonio
- PROCUREMENT
  - M. José Antonio
-關鍵語
  - M. José Antonio

RAQ

- BIOPHARMACEUTICAL
  - M. José Antonio
- BIOPHARMACEUTICAL
  - M. José Antonio
- BIOPHARMACEUTICAL
  - M. José Antonio
- BIOPHARMACEUTICAL
  - M. José Antonio
Distribution network + 70 countries; 130 partners; one shared vision

Product pipeline:
- Chlamydia trachomatis IgG
- Mycoplasma pneumoniae IgM
- Parvovirus IgG/IgM
- Cysticercosis DUO (Ag+Ab)
- Dengue DUO (Ag+Ab)

VI-Rapid® analysis

PRODUCT FEATURES
- Rapid detection - visual reading in few minutes
- User friendly protocol with little manipulation
- All the necessary reagents included in the kit
- Product control line on each device
- High sensitivity and specificity for all parameters
- Based on specific and highly purified antigens or antibodies (conjugate and line)
Immunochromatographic test

The main benefits of immunochromatographic tests are:
- Rapid detection and visual reading
- Easy performance
- No need of skilled personnel or expensive automated systems (field test)
- Appropriate pack size for diagnosis of rare disease or urgent analysis, etc.

Nowadays the tendency for the diagnosis lies in the use of more flexible techniques that are easy to perform and interpret, in order to achieve a more rapid diagnosis for the development of effective treatments.

VIRapid®

- This product line has 4 references:
  - VIRapid® MONO M&G
  - VIRapid® Legionella Culture
  - VIRapid® Hydatidosis
  - VIRapid® Tularemia

- New market opportunities, a good chance to grow and diversify sales
VIRapid® HYDATIDOSIS

The first rapid test for hydatidosis diagnosis

- Rapid detection - Visual reading in just 30 minutes
- User friendly protocol with little manipulation
- All the necessary reagents included in the kit
- Product control line on each device
- Based on specific and highly purified antigen (conjugate and line)
- Excellent performance with 94.7% sensitivity and 99.5% specificity
- CE marked (IVD)
Cyst hydatidosis is normally diagnosed by image tests. However, serological confirmation is always necessary as it can be confused with other pathologies like tumors.

- ELISA and Indirect hemagglutination (IHA) are the most popular techniques: More than 20 ELISA kits available in the market and Fumouze IHA is the market leader.

- VIRapid® Hydatidosis is unique in the market and could be a great opportunity.

- Immunochromatographic tests are user friendly and more convenient for the customer.

- A HPLC-purified *E. granulosus* 5/B enriched antigen is used in VIRAPID® HYDATIDOSIS.

The test is not able to distinguish between patients with active or inactive cysts.

- Cross-reactions with *Echinococcus alveolaris* have been reported.

- Sensitivity and specificity should be improved with recombinant antigens, instead of native antigens.
Strip Automatic Reading System

The automatic reading of the test and will reduce the subjectivity of the technician creating PDF reports for documenting the results of the analyzed samples.

The new version of the automatic reading system includes scanner, VIRapid® kit bar-coded cassette base, updated software and license for its use.

Rapid tests

Main features of the market and products
Over 20 years developing diagnostic solutions for HUMAN INFECTIOUS DISEASES